{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Black patients with ES-SCLC get less chemo, CTCs may guide breast cancer treatment, and new FDA approvals for neuroblastoma and prostate cancer","description":"Blood &amp;amp; Cancer news stories:   Black patients with ES-SCLC get less chemo but have better survival: https:\/\/bit.ly\/33Rb5eB  Should CTCs guide treatment choice in HR+, HER2\u2013 breast cancer?: https:\/\/bit.ly\/3gn6shc  New drug approved for relapsed\/refractory neuroblastoma: https:\/\/bit.ly\/2VMpvIy  FDA approves first agent for PSMA-PET imaging in prostate cancer: https:\/\/bit.ly\/36TAaY7   Contact Blood &amp;amp; Cancer at podcasts@mdedge.com. ","author_name":"Blood &amp; Cancer","author_url":"https:\/\/www.mdedge.com\/podcasts\/blood-cancer","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/17098322\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/984545\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/item\/17098322"}